ReviewFrontiers in oncology2023
Salivary glands adenoid cystic carcinoma: a molecular profile update and potential implications.
Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Ferroptosis in salivary gland disorders: mechanisms, biomarkers, and therapeutic perspectives.Apoptosis : an international journal on programmed cell death · 2026Review
- Case Report: A rare case of over 45 years' survival in a patient with tonsillar adenoid cystic carcinoma.Frontiers in oncology · 2026Article
- DLGAP5 promotes salivary adenoid cystic carcinoma proliferation and metastasis through PI3K/AKT pathway.American journal of cancer research · 2026Article
- Successful management of metachronous dual primary esophageal carcinomas: first report of consecutive adenoid cystic carcinoma and squamous cell carcinoma with exceptional treatment outcome-a case report.Frontiers in oncology · 2026Article
- Assessing the selective impact of histone modifying drugs on adenoid cystic carcinoma cells and their stem cell counterparts.BMC cancer · 2025Article
- Research on the clinical and pathological characteristics of primary orbital neoplastic lesions with communication.BMC ophthalmology · 2025Article
- Current Insights on Salivary Gland Adenoid Cystic Carcinoma: Related Genes and Molecular Pathways.Genes · 2025Review
- PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands.Journal of experimental & clinical cancer research : CR · 2025Article
- Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity.BioImpacts : BI · 2025Review
- Effect of silencing Ras homolog family member C on proliferation, invasion, and migration of salivary adenoid cystic carcinoma.Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2024Article
- Treatment of lacrimal gland adenoid cystic carcinoma: a systematic review and Meta-analysis.International journal of ophthalmology · 2024Article
- Molecular Biology and Therapeutic Targets of Primitive Tracheal Tumors: Focus on Tumors Derived by Salivary Glands and Squamous Cell Carcinoma.International journal of molecular sciences · 2023Review
- Adenoid Cystic Carcinoma of the Sinonasal Cavity: A Case Report and Literature Review.Case reports in oncologyArticle
- How predominant cell and stroma types harmonize to predict head and neck adenoid cystic carcinoma outcomes?Medical journal, Armed Forces IndiaReview
- PTEN Deregulation Mechanisms in Salivary Gland Carcinomas.Cancer diagnosis & prognosisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenoid cystic carcinoma (ACC) is an aggressive tumor with a high propensity for distant metastasis and perineural invasion. This tumor is more commonly found in regions of the head and neck, mainly the salivary glands. In general, the primary treatment modality for ACC is surgical resection and, in some cases, postoperative radiotherapy. However, no effective systemic treatment is available for patients with advanced disease. Furthermore, this tumor type is characterized by recurrent molecular alterations, especially rearrangements involving the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.